Pabosini plus cetuximab for head and neck cancer treatment with 70% focal reduction

According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent  recurrent/metastatic head and neck The overall response rate for patients with squamous cell carcinoma (HNSCC) is 39%. In a non-randomized, 3-arm, phase II trial (NCT02101034), the results of a group of studies have a median progression-free survival (PFS) of 5.4 months, a median overall survival (OS) of 9.5 months, and a 1-year OS The rate is 35%.

In this study, 30 patients with HNSCC unrelated to HPV progressed after platinum-based therapy for relapsed/metastatic disease and participated in the trial. Patients who had previously received cetuximab for relapse and HPV-related oropharyngeal cancer were not eligible. Patients received palbociclib from day 1 to day 21, 125 mg daily; cetuximab, with a starting dose of 400 mg/m 2 and then 250 mg/m 2 per week for a period of 28 days until the disease progressed or withdrew the study. The researchers performed imaging examinations before treatment and after every 2 cycles.

The median age of patients was 67 years, and the tumor sites were oral cavity (47%), larynx (27%), and oropharynx (13%). 20% of patients have local regional metastases, 27% have distant metastases, and 53% have both. Fifteen (50%) patients received ≥ 2 treatments.

Of the 28 evaluable patients, 11 (39%) had tumor responses, including 3 (11%) complete responses and 8 (29%) partial responses. Fourteen (50%) patients had stable disease, 3 (11%) patients had progression, and 70% had reduced tumor lesions.

Researcher Dr. Adkins said that Palbociclib and cetuximab have strong antitumor activity in platinum-resistant HPV-independent head and neck cancer, and biologically targeted therapy for HPV-independent head and neck cancer is an effective treatment strategy. . We look forward to the better results of the follow-up research.

Alysha Mendossa

Website |  + postsBio ⮌

• Alysha Mendossa

  https://cancerfax.com/author/alysha/

  TECARTUS (brexucabtagene autoleucel) – CAR T treatment for relapsed or refractory mantle cell lymphoma
• Alysha Mendossa

  https://cancerfax.com/author/alysha/

  Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours
• Alysha Mendossa

  https://cancerfax.com/author/alysha/

  The FDA has approved the combination of lenvatinib and pembrolizumab for advanced renal cell carcinoma
• Alysha Mendossa

  https://cancerfax.com/author/alysha/

  Pembrolizumab and lenvatinib have been approved by the FDA for advanced endometrial cancer

• Comments Closed
• June 23rd, 2020